References
- Weinstein MC, Toy EL, Sandberg EA etal Modeling for health care and other policy decisions: Uses, roles and validity. Value in Health 4(5), 348–361 (2001).
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl. J. Med 329, 977–986 (1993).
- UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonyureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 352,837–853 (1998).
- The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAIVIA 276(17), 1409–1415 (1996).
- Anonymous. Formulary development at Regence BlueShield - A formula for success. Value in Health 5(4), 297–300 (2002).
- Sullivan SD, Lyles A, Luce B eta] AMCP guidance for submission of clinical and economic evaluation data to support benefit management organizations. .Managed Care Pharmacy 7, 272–285 (2001).
- Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. PharmacoEconomics 19(6), 609–621 (2001).
Websites
- www.amcp.org/publications/format.pdf
- www.ispor.org/workpaper/healthscience/ TFModeling.pdf